Positive Results from Phase 2a Trial of DMX-200
Filed with ASX · · 4 pages · English
In the deck
Story so far
Earlier from Dimerix
- Research Validates Relevance of DMX Receptor-HIT Technology
- Investor Update
- Receipt of $420k Research & Development Tax Refund
- Corporate Presentation
- Key Patent Allowed in Japan
Later from Dimerix
- DMX-200 tablet manufacture and human study timeline
- Notice of Annual General Meeting/Proxy Form
- Dimerix Receives $545k R&D Tax Refund
- Ethics Committee Approval for Pharmacokinetic Trial
- Dimerix Phase 2a Subgroup Analysis Results
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix